Radiological and Biochemical Findings of COVID-19

Coronavirus disease-2019 (COVID-19) is a new COVID-19 that causes various health and safety concerns and socioeconomic difficulties worldwide. Early and accurate diagnosis, isolation, and management are critical public health concerns. Real-time reverse transcription polymerase chain reaction (RT-PCR) of viral nucleic acids was the reference in diagnosing COVID-19. In addition to RT-PCR, serological tests based on antibodies tested against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) have been used for diagnosis and epidemiological research. In cases where the reference tests are negative, radiological imaging guides the diagnosis. Chest radiography and thoracic computed tomography (CT) are the most commonly used radiological methods in imaging for COVID-19. Chest radiography and CT play a critical role in diagnosing, following, and staging pneumonia. However, it can also evaluate the progression of the disease, prognosis prediction, and treatment follow-up. The clinical forms of COVID-19 can range from asymptomatic infection to severe pneumonia. Biochemical findings vary in patients with different clinical forms. Therefore, biochemical parameters help diagnose the disease, determine disease severity, and predict clinical outcomes. SARS-CoV-2 is present in many tissues, including the endothelium, liver, and kidney. It can also progress with multiorgan involvement. Among the biochemical parameters, those showing organ damage play a significant role.